{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:11:18Z","timestamp":1785543078121,"version":"3.56.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1053\/j.ajkd.2020.06.017","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T11:59:36Z","timestamp":1597665576000},"page":"696-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort"],"prefix":"10.1053","volume":"77","author":[{"given":"Leslie Y.","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Romanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divjot","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon R.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ognjenka","family":"Djurdjev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Morshed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Sekirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.ajkd.2020.06.017_bib1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.5588\/ijtld.15.0081","article-title":"Risk of active tuberculosis in chronic kidney disease: a systematic review and meta-analysis","volume":"19","author":"Al-Efraij","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2020.06.017_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029563","article-title":"Risk of tuberculosis in dialysis patients: a nationwide cohort study","volume":"6","author":"Dobler","year":"2011","journal-title":"PloS One"},{"issue":"5","key":"10.1053\/j.ajkd.2020.06.017_bib3","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease","volume":"3","author":"Kato","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9888","key":"10.1053\/j.ajkd.2020.06.017_bib4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"issue":"2\/3","key":"10.1053\/j.ajkd.2020.06.017_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14745\/ccdr.v45i23a04","article-title":"Tuberculosis in\u00a0Canada: 2017","volume":"45","author":"LaFreniere","year":"2019","journal-title":"Can Commun Dis Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2020.06.017_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2016.01.034","article-title":"Tuberculosis and chronic kidney disease: an emerging global syndemic","volume":"90","author":"Romanowski","year":"2016","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2020.06.017_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1053\/j.ajkd.2020.06.017_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","article-title":"Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis","volume":"10","author":"Velenosi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"10.1053\/j.ajkd.2020.06.017_bib10","first-page":"349","article-title":"Provincial tuberculosis screening for incident dialysis patients in BC","volume":"57","author":"Cook","year":"2015","journal-title":"BC Med J"},{"issue":"6","key":"10.1053\/j.ajkd.2020.06.017_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/thx.2009.133173","article-title":"Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease","volume":"65","year":"2010","journal-title":"Thorax"},{"issue":"8","key":"10.1053\/j.ajkd.2020.06.017_bib15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1053\/j.ajkd.2020.06.017_bib16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2020.06.017_bib17","series-title":"TB in British Columbia: Annual Surveillance Report 2016","first-page":"1","year":"2018"},{"issue":"11","key":"10.1053\/j.ajkd.2020.06.017_bib18","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2020.06.017_bib19","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1002\/hpm.2495","article-title":"Barriers to treatment adherence for individuals with latent tuberculosis infection: a systematic search and narrative synthesis of the literature","volume":"33","author":"Liu","year":"2018","journal-title":"Int J Health Plann Manage"},{"issue":"11 suppl 2","key":"10.1053\/j.ajkd.2020.06.017_bib20","first-page":"S181","article-title":"Latent tuberculosis infection treatment outcomes with daily isoniazid: consistent improvement in British Columbia, 1989-2013","volume":"22","author":"Campbell","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2020.06.017_bib21","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199457110-00029","article-title":"A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients","volume":"57","author":"John","year":"1994","journal-title":"Transplantation"},{"issue":"3-4","key":"10.1053\/j.ajkd.2020.06.017_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1399-3062.2005.00103.x","article-title":"Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy","volume":"7","author":"Vikrant","year":"2005","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2020.06.017_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/TP.0b013e3181ecea8d","article-title":"Tuberculosis in renal transplant recipients: the evidence for prophylaxis","volume":"90","author":"Currie","year":"2010","journal-title":"Transplantation"},{"issue":"3","key":"10.1053\/j.ajkd.2020.06.017_bib24","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1503\/cmaj.091824","article-title":"Adverse events associated with treatment of latent tuberculosis in the general population","volume":"183","author":"Smith","year":"2011","journal-title":"CMAJ"},{"issue":"1","key":"10.1053\/j.ajkd.2020.06.017_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jmii.2018.05.003","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: high rates of adverse events","volume":"52","author":"Lin","year":"2019","journal-title":"J\u00a0Microbiol Immunol Infect"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620308970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620308970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:34:33Z","timestamp":1759462473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638620308970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0272638620308970"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.06.017","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}